Last reviewed · How we verify
Depomedrol
At a glance
| Generic name | Depomedrol |
|---|---|
| Also known as | Depomedrol 40 mg/ml, Interlaminar Epidural Injection-Standard |
| Sponsor | University of Puerto Rico |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Greater Occipital Nerve Block for Spontaneous Intracranial Hypotension
- Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement (PHASE2)
- Effects of Spencer Technique Following Hydrodilation in Patients With Adhesive Capsulitis (NA)
- MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE (PHASE2)
- Comparison of Efficacy of Intra-articular Morphine vs Methylprednisolone in Patients With Knee Osteoarthritis. (PHASE2)
- Depomedrol for Genicular Nerve Block. (NA)
- Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES) (PHASE3)
- Ultrasound-guided LMBB by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Depomedrol CI brief — competitive landscape report
- Depomedrol updates RSS · CI watch RSS
- University of Puerto Rico portfolio CI